Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer6 Nov 2026

515 Phase II biomarker study of BND-22 in combination with cemiplimab in patients with cholangiocarcinoma

Aung Naing¹
Funda Meric-Bernstam²
Milind Javle³
Bettzy Stephen²
Yali Yang¹
Tin-Yun Tang²
Mohamed H Derbala¹
Serdar A Gurses¹
Luisa M Solis Soto¹
Maria Gabriela Raso¹
Sarina A Piha-Paul¹
Apostolia M Tsimberidou⁴

6 more authors

Cara L Haymaker¹
Camila Braganca Xavier¹
Hassan A Momin¹
Ann M Cimo¹
Ecaterina E Dumbrava⁵
Natalia Ashtamker⁵

5 affiliations

¹The University of Texas MD Anderson Cancer Center, Houston, TX, USA
²1The University of Texas MD Anderson Cancer Center, Houston, TX, USA
³3The University of Texas MD Anderson Cancer Center, Houston, TX, USA
⁴The University of Texas MD Anderson Cancer Center, Houston, TX, USA7
⁵Biond Bio, Misgav, Israel

Open at source PDF DOI Cite

Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
Jin Li, Nianlan Zhou, Saiquan Lu +4
BMJ Open1 Oct 2026Peer-reviewedCC BY-NC 4.0Full textGeneral medicineCrossref
Phase 1 Study of Safety and PK With A Combination of Omeprazole and Trimetazidine for Fatty Acid Oxidation Inhibition in Patients With Advanced Solid Tumors.
Wonyoung Choi, Jung W Chun, Sung H Sim +9
Clinical and translational science28 Oct 2026Peer-reviewedCC BY-NCFull textOncologyEurope PMCPMC
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor–2 Rearrangement: Results From the Phase III FIGHT-302 Trial
Tanios Bekaii‐Saab, Davide Melisi, Hanneke W. Wilmink +24
Journal of Clinical Oncology1 Jun 2026Peer-reviewedLicence not statedFull text10 citedSurgery & anaesthesiaOpenAlex
Anti‐PD‐1/CTLA‐4 bispecific antibody‐based combination therapy for cervical cancer: a multicenter study with biomarker analysis
Jiwei Li, Yuping Deng, Tao Wu +4
Frontiers in immunology1 Oct 2026Peer-reviewedCC BYFull textOncologyEurope PMCCrossref
Biomarker-guided immunotherapy in osteosarcoma: from immune microenvironment profiling to patient stratification and combination strategies.
Qingqing Li
Frontiers in medicine9 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeX RIS

BibTeX

@article{naing2026phase,
  title = {{515 Phase II biomarker study of BND-22 in combination with cemiplimab in patients with cholangiocarcinoma}},
  author = {Aung Naing and Funda Meric-Bernstam and Milind Javle and Bettzy Stephen and Yali Yang and Tin-Yun Tang and Mohamed H Derbala and Serdar A Gurses and Luisa M Solis Soto and Maria Gabriela Raso and Sarina A Piha-Paul and Apostolia M Tsimberidou and Cara L Haymaker and Camila Braganca Xavier and Hassan A Momin and Ann M Cimo and Ecaterina E Dumbrava and Natalia Ashtamker},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0515},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0515},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - 515 Phase II biomarker study of BND-22 in combination with cemiplimab in patients with cholangiocarcinoma
AU  - Aung Naing
AU  - Funda Meric-Bernstam
AU  - Milind Javle
AU  - Bettzy Stephen
AU  - Yali Yang
AU  - Tin-Yun Tang
AU  - Mohamed H Derbala
AU  - Serdar A Gurses
AU  - Luisa M Solis Soto
AU  - Maria Gabriela Raso
AU  - Sarina A Piha-Paul
AU  - Apostolia M Tsimberidou
AU  - Cara L Haymaker
AU  - Camila Braganca Xavier
AU  - Hassan A Momin
AU  - Ann M Cimo
AU  - Ecaterina E Dumbrava
AU  - Natalia Ashtamker
PY  - 2026
DA  - 2026/11/06
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0515
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0515
SN  - 2051-1426
ER  -

Related

Cite